Biogen-IDEC Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cambridge MA United States (2003)

Organization Overview

First Clinical Trial
2003
NCT00534261
First Marketed Drug
2003
ibritumomab tiuxetan (zevalin)
First NDA Approval
2004
natalizumab (tysabri)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Biogen Idec | BIOGEN IDEC | Biogen Idec, Cambridge, MA USA | Biogen Idec. Contact for more details | BIOGEN IDEC INC | neurologyclinicaltrials@biogenidec.com